After delivery and throughout breastfeeding, GLP-1 therapy remains off-limits because semaglutide passes into breast milk and its long-term safety in infants is unknown
Blinded Procedure for NYHA Class III/IV Heart Failure (APC 1590) A randomized, double-blinded, controlled IDE study was conducted for the V-Wave interatrial shunt
~15% average weight loss Common side effects: nausea, constipation, diarrhea Also shown to reduce cardiovascular and kidney disease risks in some patients Tirzepatide (Zepbound) A dual-action medication: GLP-1 + GIP Enhances insulin, appetite control, and fat metabolism Average weight loss: ~20% in clinical trials Weekly injection Similar GI side effects to semaglutide Retatrutide (Coming Soon) A triple-agonist: GLP-1 + GIP + glucagon receptor Early studies show weight loss approaching 25% Still in clinical trials
Individuals (women and men) concerned about bone health and/or kidney health, and those on LHRH treatment or Androgen Deprivation Treatment (ADT) are the best potential candidates to take Citurol Plus
One research letter published in JAMA Oncology last year, for example, suggests GLP-1 drugs might reduce the risk of colon cancer, even among people who are not overweight
Improving metabolic health with semaglutide Studies have shown that in additional to weight loss semaglutide can have a measurably beneficial effect on metabolic health by: Reducing fasting blood glucose Lowering blood pressure Decreasing waist circumference Reducing LDL (bad) cholesterol Tirzepatides role in cardiovascular health Individuals with excess weight or obesity are at increased risk of other health issues, especially heart disease
